UB Paderborn / Katalog / Suche / in CDI

Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil

Journal of clinical pharmacology, 2019-10, Vol.59 (10), p.1331-1339

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

Clinical and translational science, 2021-09, Vol.14 (5), p.1935-1944

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers

Journal of clinical pharmacology, 2018-05, Vol.58 (5), p.666-673

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men

Clinical drug investigation, 2018-07, Vol.38 (7), p.631-638

2018

Link zum Volltext

Verfügbarkeit prüfen

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

Clinical and translational science, 2021-03, Vol.14 (2), p.599-605

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

Journal of clinical psychopharmacology, 2016-08, Vol.36 (4), p.314-323

2016

Link zum Volltext

Verfügbarkeit prüfen

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

Clinical and translational science, 2020-05, Vol.13 (3), p.462-472

2020

Link zum Volltext

Verfügbarkeit prüfen

Lack of pharmacokinetic interaction between single oral doses of letermovir (MK-8228) and fluconazole in healthy subjects

Drug metabolism and pharmacokinetics, 2019-01, Vol.34 (1), p.S39-S39

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

Clinical pharmacology and therapeutics, 2003-07, Vol.74 (1), p.17-24

2003

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies

The AAPS journal, 2008, Vol.10 (1), p.141-147

2008

Link zum Volltext

Verfügbarkeit prüfen

Relative bioavailability of diazoxide, manufactured at two different international locations, in healthy participants under fasting conditions: an open-label, two-stage, adaptive, sequential two-period crossover study

AAPS open, 2017-05, Vol.3 (1), p.1-9, Article 3

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

Clinical pharmacology and therapeutics, 2003-08, Vol.74 (2), p.150-156

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.291-300

2006

Link zum Volltext

Verfügbarkeit prüfen

Estimating time to steady state using the effective rate of drug accumulation

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2011-01, Vol.10 (1), p.27-33

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

Clinical therapeutics, 2003-05, Vol.25 (5), p.1407-1419

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

Antimicrobial agents and chemotherapy, 2021-11, Vol.65 (12), p.e0093521

2021

Link zum Volltext

Verfügbarkeit prüfen

THE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST TELCAGEPANT DOES NOT REDUCE EXERCISE TOLERANCE IN PATIENTS WITH EXERCISE INDUCED MYOCARDIAL ISCHEMIA

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A100.E939-A100.E939

2010

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects

Clinical drug investigation, 2017-06, Vol.37 (6), p.571-579

2017

Link zum Volltext

Verfügbarkeit prüfen

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

British journal of clinical pharmacology, 2013-05, Vol.75 (5), p.1240-1254

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of famotidine in infants

Clinical pharmacokinetics, 2005-01, Vol.44 (4), p.395-406

2005

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants

Clinical pharmacology in drug development, 2021-02, Vol.10 (2), p.198-206

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Antimicrobial agents and chemotherapy, 2017-12, Vol.61 (12)

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

Clinical drug investigation, 2019-05, Vol.39 (5), p.441-451

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

European journal of clinical pharmacology, 2019-05, Vol.75 (5), p.665-675

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

Lack of pharmacokinetic interaction between single oral doses of letermovir (MK-8228) and fluconazole in healthy subjects

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies

Relative bioavailability of diazoxide, manufactured at two different international locations, in healthy participants under fasting conditions: an open-label, two-stage, adaptive, sequential two-period crossover study

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

Estimating time to steady state using the effective rate of drug accumulation

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

THE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST TELCAGEPANT DOES NOT REDUCE EXERCISE TOLERANCE IN PATIENTS WITH EXERCISE INDUCED MYOCARDIAL ISCHEMIA

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

Pharmacokinetics of famotidine in infants

Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

Suchergebnisse filtern